Akt Phosphorylation at Ser473 Predicts Benefit of Paclitaxel Chemotherapy in Node-Positive Breast Cancer

PURPOSE: We tested the hypothesis that Akt-Ser473 phosphorylation (pAkt) predicts benefit from the sequential addition of paclitaxel to adjuvant doxorubicin plus cyclophosphamide (AC) chemotherapy in patients with node-positive breast cancer participating in the National Surgical Adjuvant Breast and...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Yang, Sherry X., Costantino, Joseph P., Kim, Chungyeul, Mamounas, Eleftherios P., Nguyen, Dat, Jeong, Jong-Hyeon, Wolmark, Norman, Kidwell, Kelley, Paik, Soonmyung, Swain, Sandra M.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Clinical Oncology 2010
Témata:
Original Reports
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2903333/
https://ncbi.nlm.nih.gov/pubmed/20479407
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2009.26.1602
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky